GSK:NYSE
GSK plc
46,99 $
arrow_downward
−0,40%(−0,19) 1 p
2. okt, 14:18:57 GMT −4 · USD
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse GSK põhistatistika genereerimine…
Ava
47,08 $
Kõrge
47,14 $
Madal
46,84 $
Turu kapit.
95,94 mld
Keskm. maht
3,18 mln
Maht
3,13 mln
Dividend
3,87%
Kvartaalne dividend
0,45 $
Dividendikuupäev
13. aug 2026
Hinna ja tulu suhe
15,08
52 näd kõrgeim
61,70 $
52 näd madalaim
42,84 $
Aktsiatulu
3,12 $
Beeta
0,25
Käibivad aktsiad
2,02 mld
Töötajate arv
67 tuh
Ava
47,08 $
Kõrge
47,14 $
Madal
46,84 $
Turu kapit.
95,94 mld
Keskm. maht
3,18 mln
Maht
3,13 mln
Dividend
3,87%
Kvartaalne dividend
0,45 $
Dividendikuupäev
13. aug 2026
Hinna ja tulu suhe
15,08
52 näd kõrgeim
61,70 $
52 näd madalaim
42,84 $
Aktsiatulu
3,12 $
Beeta
0,25
Käibivad aktsiad
2,02 mld
Töötajate arv
67 tuh
Uudised
Veebiallikatest ja uudistepartneritelt
Traders Union
·
9 tunni eest
Voting rights update pressures GSK stock near GBX1,847 resistance
Stock Traders Daily
·
18 tunni eest
The Technical Signals Behind (GSK) That Institutions Follow
AD HOC NEWS
·
1 päeva eest
GSK stock after-hours at EUR 21.03: minus 1.36 percent versus prior close
Traders Union
·
1 päeva eest
What's behind GSK's latest 1.8% stock pullback?
Profiil
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
Teave üksuse GSK plc kohta
TegevjuhtEmma Walmsley | Emma Walmsley
Töötajad66,8 tuh
Asutatud27. dets 2000
Peakontorid-
Sektor-
Veebisaitgsk.com